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Abstract
Flaviviruses are emerging arthropod-borne viruses representing an immense global health problem. The prominent
viruses of this group include dengue virus, yellow fever virus, Japanese encephalitis virus, West Nile virus tick borne
encephalitis virus and Zika Virus. These are endemic in many parts of the world. They are responsible for the illness
ranging from mild flu like symptoms to severe hemorrhagic, neurologic and cognitive manifestations leading to death.
NS1 is a highly conserved non-structural protein among flaviviruses, which exist in diverse forms. The intracellular dimer
form of NS1 plays role in genome replication, whereas, the secreted hexamer plays role in immune evasion. The
secreted NS1 has been identified as a potential diagnostic marker for early detection of the infections caused by
flaviviruses. In addition to the diagnostic marker, the importance of NS1 has been reported in the development
of therapeutics. NS1 based subunit vaccines are at various stages of development. The structural details and
diverse functions of NS1 have been discussed in detail in this review.
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Background
Flaviviruses belong to the family of flaviviridae, which
have 70 different antigenically related members. Most of
the flaviviruses are arboviruses (arthropod-borne viruses).
Arboviruses transmit mostly through ticks or mosquitoes
bites. According to the outbreak reports, the Dengue virus
(DENV), Japanese Encephalitis Virus (JEV), Yellow fever
virus (YFV), West Nile virus (WNV) and tick-borne En-
cephalitis virus (TBEV) are prominent human-pathogenic
flaviviruses. Recently, Zika virus outbreak has been re-
ported in various countries and has become a matter of
concern. Though, other flaviviruses (such as: St. Louis en-
cephalitis virus, Murray valley encephalitis virus, Rocio
virus, Kyasanur forest disease/Alkhurma virus, Omsk
hemorrhagic fever virus and Powassan virus) are also
pathogenic to humans but their geographical distribution
is limited. The distribution and outbreaks of flaviviruses de-
pend upon the geographic location of their vectors (mos-
quitoes and ticks) and reservoirs (birds and pigs) etc. [1].
Flaviviruses are enveloped, positive-sense, single-stranded
RNA viruses with particle size up to ~50μm in diameter.
The RNA genome of the flaviviruses contains the 5′ cap
(7mG) and 3′ CU-OH conserved tail, which directly trans-
lates into a long polypeptide in the cytoplasm of infected
cells. The polypeptide is further co-transnationally and
post-transnationally cleaved and processed by host and
viral proteases into three structural proteins: envelope
protein (E), capsid protein (C) and precursor mem-
brane protein (prM) and seven non-structural compo-
nents (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5)
(Fig. 1). Among non-structural proteins, NS1 is highly
conserved, dimer protein with the molecular weight
ranges from 46–55 kDa depending on the extent of
glycosylation. The glycosylation of NS1 is important
for efficient secretion, virulence and viral replication
[2–5]. NS1 exists as a monomer, a dimer (membrane-
bound protein, mNS1) and a hexamer (secreted pro-
tein, sNS1). NS1 is known to activate the TLRs and
inhibit the complement system [6, 7]. The intracellular
NS1 is central to viral replication, whereas the secreted
and membrane-bound NS1 have been reported to elicit
the immune response [2, 8–10].
Comparative analysis of different flaviviruses NS1 has
been performed by using a multiple alignment tool
CLUSTAL Ω. This analysis provided the regions of simi-
larity and dissimilarity among the NS1 sequences of
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different flaviviruses (Fig. 2). The CLUSTAL Ω based
analysis revealed the conserved regions of NS1 among
various flaviviruses (Fig. 2). The X-ray crystallographic
3-D structure of NS1 dimer suggests the three function-
ally distinguishable domains- a hydrophobic β-roll (a
stretch of 1–29 amino acids), α/β Wing domain resem-
bling RIG-I-like fold (38–151 amino acid residues) and a
central β-ladder (181–352 amino acid residues), stabilized
by disulfide linkages [11–13]. The association of NS1 with
the membrane and replication complex is mediated
through these three distinct structural domains. Yen et al.
[14] reported the flexible nature of core β-ladder NS1 pro-
tein. JEV NS1 has been reported as a natural viral protein
carrier for expressing the heterologous epitopes to stimu-
late the immune response against various pathogens [14].
The presence of sNS1 has been reported in circulation
during primary and secondary infections and elicits higher
concentration of IgG. The anti-NS1 antibodies have been
reported to cross-react with broader range of host proteins
like, human blood clotting factors, integrin/adhesion pro-
teins; components of ECM [15]. The cell-adhesion assays
revealed the interaction of fibronectin, plasma fibronectin
and RGD (Arginine-Glycine-Aspartic acid) containing
motif peptides with anti-NS1 (monoclonal and polyclonal)
antibodies; which intervenes in the normal functioning of
the vascular system. This probably forms the basis for the
vascular leakage in DHF/DSS patients [16].
NS1′, an extension of NS1 protein has been reported in
JEV, WNV and DENV [9]. The NS1′ is derived from viral
polypeptide; through the cleavage due to the −1 pro-
grammed ribosomal frameshift slippage, downstream of
NS2A protein. This results in the addition of extra 100
nucleotides to viral NS1 protein. NS1′ (52-53kDa) has
been implicated in neuroinvasiveness of flaviviruses [17].
General scheme of flavivirus replication
Flaviviruses are internalized into the cells by receptor-
mediated endocytosis [18]. However, several putative
receptors have been reported for the entry of flavi-
viruses, heparan sulphate proteoglycans, GRP78 (glu-
cose-regulated protein 78), Hsps (Heat shock proteins)
70 and 90, CD14, CD4, cholesterol [19, 20]. Following
their entry into the host cell, the acidic environment of
endosome un-coats the nucleocapsid and releases its
positive stranded RNA genome in the cytoplasm. The
replication of flaviviruses takes place in two phases. In
early phase of replication, the positive strand RNA be-
haves as mRNA and hijacks host factors for translation
and cleavage of polypeptide in the ER lumen by host as
well as viral proteases. In late phase of replication, the
cleaved viral proteins interact with host cellular proteins
[8, 21, 22]. The highly conserved secondary structures
present in 5′ and 3′ UTRs of flavivirus ssRNA help in
cyclization and synthesis of a complementary negative
RNA strand; where the negative-intermediate copies
serve as a template for the synthesis of new copies of the
positive stranded RNA in membrane bound vesicles
packets [23, 24]. The newly synthesized RNA copies
from the nucleocapsid complexes bud into the ER lumen
for obtaining the viral glycoproteins on the membrane.
These immature particles then trafficked through the
Golgi bodies and undergo maturation steps.
Localization, maturation and secretion of NS1
The NS1 protein plays an important role in immune in-
vasion and evasion strategies by modulating the host cel-
lular machinery for effective virus propagation. Following
the virus internalization the uncoating of nucleocapsid re-
leases the viral RNA genome in the cytoplasm where the
first round of replication occurs. The signal peptide in
viral mRNA guides it to the ER lumen, where the mem-
brane bound ribosomes translate them into structural and
non-structural proteins. The polypeptide is cleaved by
both hosts (signalases, furin) and viral serine proteases
(NS3 serine protease). The C-terminus of E protein con-
tains the signal peptide for cleaving and translocating the
Fig. 1 Flavivirus genome structure. The schematic diagram showing the processing of the flavivirus polyprotein into structural and non-structural proteins
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Fig. 2 The comparative analysis of Flavivirus NS1. Comparative analysis of Flavivirus NS1 was performed by CLUSTAL Ω software, available on
www.ebi.ac.uk/Tools/msa/clustalo/. The UniprotKB accession numbers for different flaviviruses are DENV-1 P27909, DENV-2 P29991, DENV-3
Q6YMS3, DENV-4 Q2YHF0, JEV P27395, TBEV Q01299, WNV P06935, YFV Q6J3P1, ZIKV Q32ZE1, and KUNJV P14335. The conserved sequences are
shown by asterisk (٭), the amino acids that are strongly similar in their properties, are indicated by colon (:), those amino acids that are weakly
similar, are represented by dot (.), while the dashes (−) represents the gaps among the sequences. The color-coding represents the different types
of amino acids like, Red represents small and hydrophobic amino acid, including aromatic amino acid; Tyrosine. Blue represents acidic amino
acids. Magenta represents basic amino acids. Green represents amino acids containing hydroxyl, sulfhydryl, amine groups, and Glycine amino acid.
Grey represents unusual amino/imino acids
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NS1 from translated polypeptide into ER lumen [25]. The
C-terminus of NS1 have an octapeptide sequence (L/M-
V-X-S-X-V-X-A), which is critical for cleavage and is
found to be conserved in all flaviviruses. The production
of antiviral therapies has targeted this octapeptide for the
production of NS1-based vaccines [26]. The NS1/NS2A
junction is also cleaved in ER lumen by some unknown
proteases. The cleavage and translocation of NS1 is
followed by the N-linked glycosylation in ER-lumen by
glycosidase. Studies have revealed two glycosylation sites
at Asn-130 and Asn-207, where higher orders of glycan
and mannose carbohydrate moieties are added. The C-
terminus of NS1 consist 6 pairs of cysteine residues which
form disulphide bonds and are possibly involved in dimer
formation, stabilizing the intracellular NS1 which imparts
certain level of hydrophobicity. Although NS1 lack any
membrane spanning domain, its association with plasma
membrane is quite intriguing [11]. Akey et al. [11] and
Watterson et al. [27] reported that the β-roll domain (10–
11 and 159–162 residues) of NS1 dimer protrudes out
and interacts with the ER lumen membrane. Akey et al.
[12] have further reported the membrane rearrangement
property of NS1 through an experiment, where they dem-
onstrated the ability of WNV NS1 and DENV NS1 to re-
arrange the membranes of the liposomes [11, 12, 27]. The
association of NS1 was reported to interact with choles-
terol, lipid rafts and/or GPI anchor during dimerization
[21, 28]. These findings suggest the interaction of intracel-
lular NS1 with other viral protein and host cell during dis-
ease pathogenesis is necessary [11, 29].
The intracellular NS1 (dimer) along with other non-
structural proteins and viral RNA are targeted towards
ER, forming a replication complex (RC) from ER derived
membrane structures called Vesicle Packets (VPs). RC
plays an important role in active viral replication. In
addition, the GPI-anchored NS1 and/or cholesterol/lipid
raft bound NS1 gets trafficked to either plasma mem-
brane through endocytic or secretory pathway or fuses
with trans-Golgi network for further maturation and se-
cretion [17]. The GPI-anchored form of sNS1 have been
reported to affect the signal transduction pathways to
modulate the pathogenesis of flaviviruses [30].
The trimming of carbohydrate moieties in cellular
NS1 (dimeric form) takes place in trans-Golgi net-
work by glycosidases and glycosyltransferases. These
enzymes remove complex sugars from NS1 and form
a soluble hexamer, which ultimately secretes out of
the infected cell. Unlike mammalian cells used for
protein expression, insect cells completely lack such
process and accumulates NS1 inside the cell in in-
vitro system [31]. The maturation in Golgi network is
essential for NS1 secretion, since the trimming en-
sures the removal of mannose moiety and addition of
highly complex sugars.
The sNS1 forms an open barrel shaped structure
which is associated with 70 different types of lipid mole-
cules. Further analysis of sNS1 revealed that the hex-
americ form have β-ladder and wing domain which
provides an accessible area for interaction with hosts
proteins, while the β-roll domain remains associated
with central lipid channel [11].
Role of NS1 in replication of flavivirus
Flaviviruses hijack host proteins in order to complete
their genome replication and translation of viral poly-
peptide. Replication occurs in virus-induced membrane
structure (IMS) derived from ER membrane known as
Vesicle Packets (VPs) [32]. The remodeling ability has
been shown by both NS4A, NS4B and NS1 proteins [12]
which helps in formation of VPs [33].
The biochemical experiments in case of other flavi-
viruses have shown the association of NS1 with transmem-
brane NS4B [19, 29]. The transmembrane N-terminal of
NS4A and NS4B interacts with hydrophobic β-roll of NS1
and stabilizes the transmembrane protein in the lumen of
ER and helps in viral replication [29]. Muller et al. [17]
have proposed a model where DENV RC is formed within
VPs [17]. The Asn-130 plays role in viral replication while
Asn-207 is involved in NS1 secretion from infected cells.
The abrogation of glycosylation at Asn-130 in DENV sero-
types 1 and 2 and YFV NS1 has been implicated in sup-
pression of viral replication in both infected mammalian
and insect cells [4, 34, 35]. However, Fan et al. [36] re-
ported that the deletion mutant of Asn-207 in DENV-2
NS1, resulted into the suppression of viral replication in
BHK-21 and Vero cells, which is inconsistent with the earl-
ier reports [36].
Functions of NS1′
NS1′ is an extended version of NS1 protein with the
molecular weight of 52–53 kDa. The protein is identified
in extracellular milieu during JEV, WNV and DENV in-
fections [9, 37, 38]. Earlier it was speculated that NS1′ is
produced by alternative splicing, downstream of NS2A
gene while bioinformatics and mutational studies in
WNV (Kunjin strain) identified a slippery heptanucleo-
tide (YCCUUUU) followed by a pseudoknot structure at
the N-terminal of NS2A gene [37]. The presence of both
slippery heptanucleotide and pseudoknot structures re-
sult in −1 ribosomal frameshift; which leads to an
addition of 52 amino acids at C terminal of NS1 genes
[37, 39]. This additional peptide (FS52aa) was found to
be immunogenic and raised antibodies in mice [40].
A single nucleotide mutation in JEV (G66A) and
WNV (A30P) NS2A gene disrupts the formation of
NS1′ leading to reduced neuroinvasiveness [37, 41]
Satchidanandam et al. [42] and Takamatsu et al. [43] re-
ported the association of flavivirus NS1′ with NS3 and
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NS5 inside replication complex in mammalian and avian
cells [42, 43]. Later on, WNV NS1′ was shown to co-
localize with NS1 in the ER and plays a role in viral rep-
lication where it substitutes NS1 function [44].
The secreted form of NS1′ has been reported in both
infected mammalian and insect cells. The glycosylation
events add higher order of mannose sugar to both sNS1
and sNS1′ in these cells. In mammalian infected and
transfected cells, JEV NS1 and NS1′ secrete out slowly
in extracellular milieu while in insect cells they retain
back in cellular layers [9]. The retention of NS1′ was
later on explained by the presence of 20 amino-acids at
C-terminal of WNV NS1′ protein. The hydrophobic do-
mains of NS1′ helps in attachment to the ER membrane
and remain inside the cell [45].
Interaction of NS1 with host proteins
Intracellular NS1 interacts with various host proteins to
assist the viral replication, translation and virion pro-
duction. The NS1 interacts with ribosomal proteins of
60S ribosome subunit: RPL18, RPL18a and RPL7. These
ribosomal proteins are involved in translation as well as
in some extra-ribosomal functions like, interaction with
IRES (internal ribosomal entry sites) or anchoring the
ribosomes to ER membrane. During flavivirus infection,
NS1 interacts and re-localizes these proteins at the site
of viral replication. siRNA based studies have shown
the decreased viral translation, replication and virion
production [46].
Heterogeneous nuclear Ribonucleoprotein C1/C2 and
K [hnRNP C1/C2] are RNA binding proteins of nucleus
and involved in mRNA processing, regulation of gene
expression and maintenance of cellular homeostasis.
During viral infection, hnRNPC and K proteins re-
localize in cytoplasm and regulate the viral translation,
replication, apoptosis in infected cell and disease patho-
genesis [47, 48]. DENV NS1 along with hnRNP C1/C2,
K and vimentin was reported to interact during DENV
infection and help in virus propagation [49, 50].
Dechtawewat et al. [51] reported the co-localization of
36 cellular proteins with DENV NS1. Among them,
NEK-2 (human NIMA-related kinase 2) regulates the
cell-cycle; TOA-1 (thousand and one amino acid protein
kinase 1) regulates apoptosis while COG-1 (component
of oligomeric Golgi complex 1) has been reported in
modification and transport of DENV NS1 [51].
Virus replication and translation process requires en-
ergy. Allonso et al. [52] reported the re-localization of
GAPDH near viral replication by NS1 during DENV in-
fection. The intracellular NS1 increases the glycolic flux,
leading to glycolysis, which results in the release of en-
ergy utilized by DENV (16681 strain) during replication
and translation [52].
The STAT family is involved in signal transduction
and transcription factors upon activation by JAK kinases.
STAT3β is an isoform of STAT3 α protein; member of
STAT family. The SH2 and SH3 domains of STAT3 have
been reported to interact with NS1 protein, which re-
sults into the release of TNF-α and IL-6 in response to
the infection [53].
Identification of NS1 interacting partners will be help-
ful in elucidating the mechanism of pathogenesis of fla-
vivirus infection.
NS1 and Toll-like receptors
The intracellular and sNS1 play a crucial role in both
suppression and activation of various cellular responses
during Flavivirus infection. RIG-I (retinoic-acid-inducible
gene I), MDA-5 (melanoma-differentiation–associated
gene 5) and RIG-I-like receptors, (RLRs) recognize the
viral RNA and respond via interferon signaling to pro-
tect the cell against viral infection (Fig. 3 (13)) [54].
TLRs are the membrane spanning PRRs (pattern recog-
nition receptors), present either on cell surface or in
endosomes and recognize PAMPs (pathogen associated
molecular patterns) on invading pathogens. TLRs have
been implicated in recognizing various flaviviruses,
where they either increase or suppress the immune re-
sponses against pathogens.
There are contradictory reports on TLR3, where the
presence of TLR3 augments WNV infection in mice
model [55–57]. However, another study by Daffis et al.
[58] reported inhibitory role of TLR3 during WNV in-
fection [58]. Further, Baronti et al. [59] reported no role
of NS1 in TLR3 signaling in WNV, YFV and DENV-2
[59], while Crook et al. [60] recently demonstrated the
suppression of TLR3 signaling pathway by sNS1 based
on in-vitro and in-vivo studies [60].
Activation of TLR2 and TLR6 by sNS1 during DENV
infection has been reported to increase the production
of proinflammatory cytokines like IL-6 and TNF-α
(Fig. 3 8b) [61]. Modhiran et al. [62] reported the po-
tential involvement of TLR4 in the recognition of sNS1
of DENV. The sNS1 has been reported to activate the
macrophage and peripheral blood mononuclear cells
(PBMCs) via TLR4, which led to the expression of pro-
inflammatory cytokines. The increased production of
these proinflammatory cytokines disrupts the integrity
of endothelial cells. Furthermore, TLR4 antagonist and
anti-TLR4 antibody treatment inhibited the vascular
leakage, a characteristic hallmark of dengue disease se-
verity. These findings suggest the interaction of NS1
with the TLRs [62].
The above mentioned reports show the dynamic role
of intracellular and sNS1 during the Flavivirus infection.
Also, how the NS1 is involved directly or indirectly dur-
ing flavivirus pathogenesis.
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NS1 and complement activation
Complement system is an effector arm of antibody-
mediated response against pathogens. It became evident
through various studies that infected cells express both
membrane-bound and sNS1 in extracellular milieu. Sev-
eral proteins of complement system such as C3, C4, C5,
clusterin, factor H (fH) and factor D have been reported
to interact with sNS1 (Fig. 3). The sNS1 and membrane
bound NS1 have been reported to activate the comple-
ment system via forming a membrane attack complex
(C5b-9) and SC5b-9 (soluble terminal complement com-
plex); which further increases the secretion of vasoactive
cytokines resulting in disease severity, (Fig. 3) (9) [63].
Kurosu et al. [64] reported the interaction of sNS1 and
clusterin, during DENV infection (Fig. 3) (10). They re-
ported that clusterin inhibits the SC5b-9 formation but
its interaction of sNS1 with clusterin increased the level
of SC5b-9 [64]. The C4 protein has been reported to
promote the inflammatory response. The sNS1 was
found to stimulate classical/lectin pathway by binding
and cleaving C4 to C4b; (Fig. 3) (12). Co-precipitation
experiments revealed the interaction of sNS1 with
proC1s/C1s and C4, this complex inhibits the concen-
tration of C4 and protects the neutralization of infected
cells. The extracellular sNS1 forms the complex with C4
and C4 binding protein1, which inhibits the viral recog-
nition by host cell and protect the complement mediated
lysis of infected cells in DENV, WNV and YFV [5, 65].
Fig. 3 The diagrammatic representation of Flavivirus NS1 and its interacting partners. 1-The infected cell releases the virion particles and infects
the endothelial cells via several putative receptors present on cell surfaces, 2-3-The secreted and membrane-bound NS1 interacts with several
host immune cells like, Macrophages, Basophils, Monocytes and Platelets; along with IgG and IgM anti-NS1 Antibodies produce during Flaviviral
infection, 4-6-The immune complex (the anti-NS1 Abs and sNS1) activates the Fc-γ receptor present on those immune cells and release the
vasoactive cytokines, which further increases the vascular permeability, 7-The sNS1 efficiently interacts with IgM anti-NS1 antibodies and
inhibits the classical pathway of complement system, 8-The sNS1 activates the Toll-like receptors like2,3,4,6 and 7 present on cell surface or
within endosomes of cell which further releases the inflammatory responses and disrupts vascular integrity, 9-sNS1 associates with factor H of
complement system and inhibits the membrane attack complex (MAC) formation, thus inhibiting the alternative pathway of complement
system, 10-The binding of sNS1 to clusterin protein activates the formation of C5b-9 and SC5b-9 formation which increases the cytokine
storm, 11-Also, anti-NS1 antibodies activate the platelet aggregation and/or Antibody-independent phagocytosis, which further aggravates
the situation, 12-The NS1-C1 interaction not only breakdown C4 into C4a and C4b but also interacts with C4BP, a recurring protein on infected
cell and inhibits the aggregation of C3 and C4b on infected cell and prevent the MAC formation which ultimately blocks the classical and
lectin pathway,13-The RIG-1 and MDA-5 helicases recognizes the single and double stranded RNAs and increases the activation of inflammatory and
antiviral cytokines
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The plasma glycoprotein factor H (fH) is one of the cru-
cial regulators of alternative complement pathway [66]
and has been exploited by sNS1 in immune evasion
strategy. The interaction of WNV NS1 with fH (WNV
NS1-fH), degrades the C3b convertase and restricts the
formation of C5b-9 membrane attack complex on in-
fected cells [67]. However, Krishna et al. [68] did not
find any interaction between JEV NS1 and fH comple-
ment protein [68].
The interaction of sNS1 with C1q has also been re-
ported to play role in Antibody dependent enhance-
ment (ADE) [69–71] (Fig. 3) (7–9). The crosstalk
between sNS1 and acute phase proteins (APPs) leads to
the enhanced acute phase response (APRs) in DENV
infection. The APPs play important roles in innate im-
mune response like, inflammation, infection, trauma or
stress. The increased levels of APPs might lead to the
pathophysiological conditions like thrombocytopenia,
hemorrhage and disruption of vascular integrity as re-
ported in DHF/DSS cases [72, 73].
Role of NS1 in disease diagnosis and therapeutics
Quick adaptation of virus to changing environment, di-
verse geographical distribution and lack of effective vec-
tor control approaches ultimately led to the global
burden of the flavivirus-associated diseases. Many strat-
egies have been utilized for the diagnosis of flavivirus
infections. The sNS1 protein in serum has been used as
a diagnostic marker in flaviviral infections. Based on
the clinical symptoms virus culture, RT-PCR and
immuno-histological tools can be applied for detection
of flavivirus infection [74]. The NS1 antigen-based
ELISA has been used as a diagnostic tool in JEV, WNV
and DENV infections [75, 76]. The newer approaches
like the biosensor-based approaches, immuno-spot as-
says using fluorescent and opto-magnetic nanoparticles,
electrochemical detection using carbon nanotube layer-
ing and surface plasmon resonance-based immuno-
sensors have been tried at the various stages to quantify
the NS1 from patient samples [77–80]. Several studies
based on TLRs and NS1 interaction pointed out the use
of TLR antagonists and anti-NS1 antibodies as thera-
peutics [61, 62, 81].
Various attempts have been made for NS1 based sub-
unit and DNA vaccine against JEV, DENV and YFV. The
NS1 based subunit vaccine (fusion protein of prM/E and
NS1 protein or recombinant purified NS1) has been re-
ported to be reactive against anti-NS1 antibodies and
was found to be partially protective against infections
[82–86]. Beatty et al. [81] reported the inhibitory effect
of NS1-immune polyclonal serum and anti-NS1 mAbs
on DENV-2 NS1 induced vascular leakage, both in vivo
and in vitro [81]. To ascertain the safety and efficacy of
NS1 based vaccine, the different formulations with
different adjuvants were co-administered with recombin-
ant NS1 in mice, which resulted into partial protection
against flavivirus-induced lethal encephalitis [85, 87].
The NS1 based vaccine has been tested for its efficacy
in flaviviral infections using the different constructs,
DENV-NS1 lacking the C-terminal amino acids 271–352
(DCNS1), and chimeric DJNS1 (consisting of N-terminal
DENV NS1 amino acids 1–270 plus) C-terminal of JEV
NS1 amino acid 271–352. The modified forms of NS1
proved to be of better efficacy than unmodified NS1 in
controlling flaviviral infections [84]. The NS1 based
DNA vaccination against JEV and DENV have been re-
ported to enhance the survival rate in mice by eliciting
both cellular and humoral responses [88, 89].
Since NS1′ and NS1 co-exist in host cell, the expres-
sion of NS1′ revealed a negative effect on JEV infection
and may have harmful effects on NS1 based DNA vac-
cines [90]. The cross-reactivity of WNV NS1 antibodies
against JEV infection leads to a protective role; while
DENV NS1 antibodies have a pathogenic role in increas-
ing disease severity [15, 75, 90–94]. The purified recom-
binant NS1 protein either from the bacterial, yeast or
mammalian expression system, retains its antigenicity
and reported to be reactive against monoclonal or poly-
clonal anti-NS1 antibodies. Many in vitro and in vivo
studies reported the partial or complete protection in re-
sponse to polyclonal and monoclonal anti-NS1 anti-
bodies treatment against mosquito-borne flaviviruses,
reflecting the potentiality of NS1 as a vaccine candidate.
NS1 based vaccines are in various stages of develop-
ment for providing better protection against the flavi-
viruses. Ishikawa et al. [86] developed a tripliVAX JE
chimeric vaccine by substituting the JEV prM/E and
WNV NS1 (RepliVAX JE) with JEV prM/E and JEV NS1
genes. The RepliVAX JE vaccine provided absolute pro-
tection from JEV infection by producing higher neu-
tralizing antibodies in mice but its efficacy got
compromised due to the presence of pre-existing anti-
NS1 antibodies [86].
Conclusion
Flavivirus infections have been reported as emerging in-
fections over the past decades. The diagnostic and thera-
peutic tools are still a major challenge for most of the
flavivirus infections but a significant progress has been
made towards the development of such tools. The anti-
bodies against the flaviviral NS1 proteins play a central
role in prophylaxis and/or treatment of flavivirus infec-
tion through passive immunization. The higher concen-
tration of NS1 directly correlates with disease severity
and increased viremia. The NS1 protein is an important
target for inhibitor design. The secreted and cell-
surface-associated NS1 are highly immunogenic. The
NS1 is an important biomarker for early diagnosis of the
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flaviviral infections. The information about the molecu-
lar structure and the interacting partners of NS1 pro-
vided better understanding about the role of NS1 in the
pathophysiology of flavivirus-associated infections.
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